Brean Capital Maintains Hold On Biomarin Following In-Line 3Q14
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Hold rating on Biomarin Pharmaceutical (NASDAQ:BMRN), as the company reported total revenue of $177 million, in-line with consensus of $206 million, when considering that consensus was a mix of including and not including a one-time revenue item. GAAP EPS was $0.05 in 3Q14, beating consensus of $(0.22) due to $67.5 million from the sale of the Priority Review voucher. No price target was provided.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 11.8% and a 60.5% success rate. Aschoff has a 37.3% average return when recommending BMRN, and is ranked #193 out of 3343 analysts.